Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

SELLAS Life Sciences Soars After Phase 3 AML Trial Meets Primary Goal

None

SELLAS Life Sciences Group (SLS) is up 220.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is SELLAS announcing positive topline data from its pivotal Phase 3 REGAL trial in acute myeloid leukemia. The update appears especially market-moving because the study met its primary endpoint on overall survival, which can materially improve the odds of a future regulatory filing and potential commercialization.

Details:

  • SELLAS said galinpepimut-S in the Phase 3 REGAL trial delivered a statistically significant improvement in overall survival versus best available treatment in AML patients in second or later remission.
  • The company disclosed a 41% reduction in the risk of death, with median overall survival of 24.0 months for treated patients versus 14.7 months for the comparison arm.
  • Management said it plans to meet with the FDA while preparing for a Biologics License Application, suggesting the program could be moving from late-stage development toward a regulatory path.
  • The move may have been amplified because SELLAS had already flagged this month as the expected timing for the REGAL topline readout, making today’s result a major binary event for the stock.
  • Sources:

    SEC, SELLAS Life Sciences, GlobeNewswire

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $SLS Hedge Fund Activity

    We have seen 138 institutional investors add shares of $SLS stock to their portfolio, and 77 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles